Opendata, web and dolomites

PHARMS SIGNED

Bacteriophage inhibition of antibiotic-resistant pathogenic microbes and founding for novel therapeutic strategies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PHARMS project word cloud

Explore the words cloud of the PHARMS project. It provides you a very rough idea of what is the project "PHARMS" about.

complement    life    transcription    unknown    amr    culture    positioned    vivo    molecular    isolate    phage    multiple    time    framework    scientific    translation    action    ways    limited    mechanisms    acinetobacter    diseases    delivered    resistant    driving    plan    natural    group    vectors    helicobacter    elucidating    bacteriophages    threatening    screen    throughput    discoveries    battery    alien    utilizes    elucidate    functions    levels    antimicrobial    pylori    tools    therapies    bacterial    fight    universal    vitro    independent    peptides    deploy    lines    pathogens    interdisciplinary    sequence    700    biology    mimic    mediated    infectious    ranging    antibiotics    isolates    discovered    inhibitors    pharms    emergence    viruses    multifaceted    validation    nucleotide    discover    clinical    engineer    baumannii    rational    building    array    bactericidal    confirmation    encoded    people    worldwide    host    revolutionary    genes    synthetic    phages    therapeutic    enzymes    resistance    modes    employ    strategies    wp1    killed    wp3    therapy    obstacles    treating    bacteria    grand    transport    wp2    influenzae    inhibition    haemophilus   

Project "PHARMS" data sheet

The following table provides information about the project.

Coordinator
HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH 

Organization address
address: INGOLSTADTER LANDSTRASSE 1
city: NEUHERBERG
postcode: 85764
website: www.helmholtz-muenchen.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 1˙499˙650 €
 EC max contribution 1˙499˙650 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-STG
 Funding Scheme ERC-STG
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2023-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH DE (NEUHERBERG) coordinator 1˙499˙650.00

Map

 Project objective

Emergence of antimicrobial resistance (AMR) is a grand scientific challenge of our time that has killed more than 700,000 people worldwide. Phage therapy, a promising complement to antibiotics, utilizes viruses of bacteria (bacteriophages) or phage-derived inhibitors as natural ways to fight AMR. The main obstacles in the clinical application of phage-based AMR therapy are the limited number of phage isolates and the unknown molecular mechanisms of phage-delivered bactericidal action. Building on the recent advances of my group in high-throughput, culture-independent but host-targeted methodologies, PHARMS aims to deploy a revolutionary approach: to screen for all possible phages of a resistant bacterial isolate, characterize multiple lines of their bactericidal functions, and use this information for the design of a whole battery of phage-based therapies that employ multifaceted modes of action.

Using an interdisciplinary research plan, PHARMS will discover phage-specific bactericidal action modes at all possible levels ranging from nucleotide sequence and transcription to translation, in order to elucidate the molecular mechanisms driving phage-mediated inhibition of AMR Acinetobacter baumannii, Helicobacter pylori, & Haemophilus influenzae (WP1). These discoveries, together with novel synthetic biology tools, will enable us to engineer an array of phage vectors that mimic phage-deployed bactericidal modes discovered under WP1, including transport of alien genes to deliver bactericidal effects (WP2). PHARMS will provide molecular confirmation and in vitro & in vivo validation of the functions of phage-encoded bactericidal peptides and enzymes (WP3). By elucidating universal and specific mechanisms of phage-delivered inhibition of AMR pathogens, PHARMS is positioned to provide the rational framework for the design of novel therapeutic strategies aimed at treating common and life-threatening infectious diseases.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PHARMS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PHARMS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

Aware (2019)

Aiding Antibiotic Development with Deep Analysis of Resistance Evolution

Read More  

Resonances (2019)

Resonances and Zeta Functions in Smooth Ergodic Theory and Geometry

Read More  

PonD (2019)

Particles-on-Demand for Multiscale Fluid Dynamics

Read More